M5717 200 mg

DRUG2 trials

Sponsors

Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany

Conditions

HealthyMalaria Infection

Phase 1

Chemoprophylactic Activity of M5717 in PfSPZ Challenge Model

CompletedNCT04250363

Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, GermanyHealthy

Start: 2020-02-17End: 2021-08-18Updated: 2024-05-01

Phase 2

Efficacy, Safety, and PK of M5717 in Combination With Pyronaridine as Chemoprevention in Adults and Adolescents With Asymptomatic Plasmodium Falciparum Infection (CAPTURE-2)

CompletedNCT05974267

Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, GermanyMalaria Infection

Start: 2023-11-28End: 2024-12-29Updated: 2026-02-06

Related Papers

Causal chemoprophylactic activity of cabamiquine against Plasmodium falciparum in a controlled human malaria infection: a randomised, double-blind, placebo-controlled study in the Netherlands.

2023-07-0316 citations